G. Pozza

Vita-Salute San Raffaele University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Antonio Secchi

Vita-Salute San Raffaele University

105

Valerio Di Carlo

Institute for Bioengineering of Catalonia

Antonio E. Pontiroli

University of Milan

Federico Bertuzzi

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

C. Socci

Vita-Salute San Raffaele University

Lucilla D. Monti

Vita-Salute San Raffaele University

P. Micossi

IRCCS Policlinico San Donato

R. Castoldi

IRCCS Ospedale San Raffaele

Paola Maffi

IRCCS Ospedale San Raffaele

Emanuele Bosi

Vita-Salute San Raffaele University

Cooperative Institutions

University of Milan

489

Istituti di Ricovero e Cura a Carattere Scientifico

323

San Raffaele University of Rome

287

Vita-Salute San Raffaele University

283

Inserm

222

IRCCS Ospedale San Raffaele

199

University of Padua

169

Sapienza University of Rome

147

University College London

144

Harvard University

143

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Impairment of Lymphocyte-Suppressive System in Recent-Onset Insulin-Dependent Diabetes Mellitus: Correlation With Metabolic Control

Diabetes (1986)

Francesca Crosti Antonio Secchi Elisabetta Ferrero Luca Falqui Luca Inverardi

Impairment of suppressor-cell activity may be important in the pathogenesis and maintenance of insulin-dependent diabetes mellitus (IDDM). In 23 recent-onset IDDM patients, lymphocyte sensitivity in vitro to theophylline was tested both in basal conditions and after improvement of metabolic control. This pharmacologic agent is mainly effective on a lymphocytic subpopulation with phenotypic and functional suppressive features. Peripheral blood lymphocytes from IDDM patients showed a loss of theophylline sensitivity, identified as inhibition of both E-rosette formation and blastogenic response to polyclonal mitogens concanavalin A (ConA) and phytohemagglutinin (PHA). An inverse relationship was demonstrated between the theophylline-induced suppression of ConA blastogenic response and blood glucose and glycosylated hemoglobin levels (P less than .01). Metabolic control seemed to be important even in relation to lymphocyte subpopulation distribution. In IDDM patients we found a significant (P less than .05) reduction of OKT4+ lymphocytes that is correlated with blood glucose and glycosylated hemoglobin levels (P less than .01). The improvement of metabolic control led to recovery of theophylline sensitivity. We suggest a deficiency in a suppressive system that could be involved in IDDM onset and the possible role of metabolic control in the impairment of some immunologic functions reported with this pathologic condition.

Metabolic control analysis

Basal (medicine)

10.2337/diab.35.9.1053

Cite

Citations (15)

Intranasal Glucagon as Remedy for Hypoglycemia: Studies in Healthy Subjects and Type I Diabetic Patients

Diabetes Care (1989)

Antonio E. Pontiroli A. Calderara E. Pajetta M. Alberetto G. Pozza

Intranasal glucagon can raise blood glucose levels in healthy subjects. The aims of this study were to 1) compare the hyperglycemic effect of intranasal and intramuscular glucagon in healthy subjects and type I (insulin-dependent) diabetes patients during euglycemic conditions and 2) test the efficacy of intranasal and intramuscular glucagon in counteracting hypoglycemic episodes in insulin-treated diabetic patients. Intranasal glucagon raised blood glucose levels in both healthy subjects and type I diabetic patients, the effect of intramuscular glucagon being similar for the first 30 min and higher thereafter. Intranasal glucagon was also quicker acting than oral glucose in healthy subjects. Intranasal glucagon raised blood glucose levels in patients with hypoglycemic episodes, although less effectively than intramuscular glucagon. These data indicate intranasal glucagon as a possible emergency remedy for self-medication in insulin-treated patients prone to hypoglycemic episodes.

10.2337/diacare.12.9.604

Cite

Citations (41)

Inhibition of Basal and Metoclopramide-Induced Prolactin Release by Cabergoline, an Extremely Long-Acting Dopaminergic Drug

The Journal of Clinical Endocrinology & Metabolism (1987)

A. E. Pontiroli L. Cammelli Paolo Baroldi G. Pozza

The aim of this study was to evaluate the effectiveness of the ergoline derivative cabergoline in inhibiting the serum PRL response to metoclopramide (MCP; 5 mg, iv) and the duration of this effect. Seven normal men received cabergoline (600 micrograms, orally) on day 0 and underwent a MCP test on days -1, 1, 4, 8, 15, and 28. Fasting serum PRL levels were significantly depressed from days 1-14; the nadir value occurred on day 4. MCP-induced PRL release was significantly inhibited up to day 28, with a nadir on day 4. Two months later, four of the men received placebo on day 0, and tests with MCP were performed on days -1, 8, and 28; basal serum PRL levels and PRL responses to MCP were superimposable on days -1, 8, and 28. These data indicate that cabergoline is an effective long-acting inhibitor of PRL release in normal men, suitable for use in the management of hyperprolactinemic patients.

Cabergoline

Metoclopramide

Basal (medicine)

10.1210/jcem-65-5-1057

Cite

Citations (22)

Analgesic effect of intranasal and intramuscular salmon calcitonin in post-menopausal osteoporosis: A double-blind, double-placebo study

Aging Clinical and Experimental Research (1994)

Antonio E. Pontiroli E. Pajetta Luisa Scaglia Alessandro Rubinacci Giuseppina Resmini

Placebo-controlled study

Intramuscular injection

10.1007/bf03324278

Cite

Citations (37)

Lipid metabolism after successful kidney and pancreatic transplantation.

PubMed (1991)

E. La Rocca Antonio Secchi Mariella Parlavecchia Santica M. Marcovina Giacomo Ruotolo

Source

Cite

Citations (8)

Functional study of insulin secretion pattern following segmental neoprene-injected pancreatic allograft in insulin-dependent (type 1) diabetic recipients.

PubMed (1983)

J Traeger Dubernard Jm G. Pozza Antonio Secchi Emanuele Bosi

Neoprene

Source

Cite

Citations (2)

[Vascular access for chronic hemodialysis in diabetic patients].

PubMed (1991)

Donatella Spotti Giorgio Slaviero Giuliana Ferrari Michele Carlucci Roberto Chiesa

The aim of this study carried out on 33 uremic diabetic patients submitted to chronic hemodialytic treatment was to assess the kind of complications related to the vascular approach used as well as their short- and long-term incidences. Out of the 46 anastomoses prepared, 39 were arteriovenous fistulae according to Brescia-Cimino and 7 were PTFE grafts. The actuarial survival rate was 88%, 79%, and 63% after one, two and four years, respectively. The most frequent compliance was thrombosis. Our experience demonstrates that the distal arteriovenous fistula may be considered a valid vascular access for hemodialysis also in diabetic patients.

Arteriovenous Anastomosis

Source

Cite

Citations (2)

The concomitants of elevated erythrocyte sodium - lithium countertransport activity in diabetic nephropathy: a critical assessment

Acta Diabetologica (1992)

Ruggero Mangili Daniela Gabellini G. Pozza

Genetic predisposition

Essential hypertension

10.1007/bf00573492

Cite

Citations (3)